Schroder Investment Management Group Purchases 8,432 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Schroder Investment Management Group boosted its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 1.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 485,145 shares of the company’s stock after acquiring an additional 8,432 shares during the period. Schroder Investment Management Group owned 0.77% of Vera Therapeutics worth $20,405,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in VERA. AlphaQuest LLC acquired a new position in Vera Therapeutics during the 4th quarter valued at about $34,000. KBC Group NV raised its stake in shares of Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after buying an additional 1,387 shares during the last quarter. Moors & Cabot Inc. acquired a new position in Vera Therapeutics in the fourth quarter valued at approximately $220,000. E Fund Management Co. Ltd. boosted its stake in Vera Therapeutics by 22.3% in the fourth quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock valued at $262,000 after acquiring an additional 1,130 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in Vera Therapeutics during the 4th quarter worth $431,000. Institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on VERA shares. Wolfe Research assumed coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target on the stock. Guggenheim increased their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price objective for the company. Finally, JPMorgan Chase & Co. reduced their price target on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Vera Therapeutics presently has an average rating of “Buy” and a consensus price target of $64.67.

Insiders Place Their Bets

In other news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total value of $730,450.00. Following the sale, the chief executive officer now directly owns 143,603 shares in the company, valued at $5,993,989.22. This trade represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 21.70% of the company’s stock.

Vera Therapeutics Trading Up 7.1 %

Shares of NASDAQ:VERA opened at $23.59 on Thursday. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -9.04 and a beta of 1.17. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 12 month low of $21.45 and a 12 month high of $51.61. The company’s fifty day simple moving average is $30.30 and its 200 day simple moving average is $38.59.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. As a group, research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.